WhaleCreep

RA Capital Management, L.P. 13F holdings, Q2 2018

Hedge fundSEC filingsCompare with another fundHoldings as of 2018-06-30, filed 2018-08-14

RA Capital Management, L.P. disclosed 27 US equity positions worth $1.5bn in its Q2 2018 13F filing. Its largest position is WVE at 18.7% of the reported book, followed by ASND and SLDB. Versus Q1 2018 it opened 4 new positions, added to 4, reduced 1 and exited 8.

$1.5bn
Reported equity book
Sum of the long US equity positions in the filing, at the values filed. Options are excluded.
27
Positions
Distinct securities in the equity book with a reported value above zero. Options are excluded.
18.7%
Largest position
The largest single position as a share of the reported equity book.
73.5%
Top 10 weight
The ten largest positions together, as a share of the reported equity book.
11
Effective positions
1 / HHI of portfolio weights: the number of equal-weight positions the book behaves like.
73
Quarters on file since Q4 2007
Quarters for which this manager's 13F holdings are on record.

Holdings

Against Q1 2018: 4 new, 4 added, 1 reduced, 8 exited

27 rows
WVE WAVE LIFE SCIENCES LTDHealthcare18.7%$287m7.51m0.0%held
ASND ASCENDIS PHARMA A/SHealthcare18.3%$282m4.24m0.0%held
SLDB SOLID BIOSCIENCES INCHealthcare6.2%$95.8m2.69m0.0%held
ENDOCYTE INC no ticker–5.1%$78.0m5.65m+46%added
MNTA MOMENTA PHARMACEUTICALS INC–4.9%$75.7m3.70m–new
IMMU IMMUNOMEDICS INC–4.8%$73.8m3.12m–new
MYOVANT SCIENCES LTD no ticker–4.2%$64.7m2.83m0.0%held
IFRX INFLARX NVHealthcare4.1%$63.4m1.97m+21%added
TGTX TG THERAPEUTICS INCHealthcare3.7%$56.3m4.28m+73%added
SG7 SAGE THERAPEUTICS INC–3.6%$54.9m350,933−0.6%reduced
ZGNXEUR ZOGENIX INC–3.3%$50.6m1.15m0.0%held
RYTM RHYTHM PHARMACEUTICALS INCHealthcare3.1%$48.2m1.54m–new
DRNAUSD DICERNA PHARMACEUTICALS INC–3.1%$48.2m3.93m0.0%held
EIDXGBP EIDOS THERAPEUTICS INC–2.9%$44.0m2.16m–new
BCRX BIOCRYST PHARMACEUTICALS INCHealthcare2.6%$40.0m6.98m0.0%held
RARXEUR RA PHARMACEUTICALS INC–2.5%$38.3m3.85m0.0%held
KALA PHARMACEUTICALS INC no ticker–1.9%$29.0m2.11m0.0%held
APLSUSD APELLIS PHARMACEUTICALS INC–1.3%$19.8m900,0000.0%held
CLEARSIDE BIOMEDICAL INC no ticker–1.1%$16.3m1.52m0.0%held
SCPH SCPHARMACEUTICALS INC–1.0%$16.2m2.86m0.0%held
IOVA IOVANCE BIOTHERAPEUTICS INCHealthcare0.9%$14.4m1.12m+70%added
4XC1 KALVISTA PHARMACEUTICALS INC–0.8%$11.7m1.44m0.0%held
AVEOEUR AVEO PHARMACEUTICALS INC–0.7%$11.4m5.06m0.0%held
SPRO SPERO THERAPEUTICS INCHealthcare0.7%$10.9m741,6470.0%held
GLYCEUR GLYCOMIMETICS INC–0.3%$4.1m253,5470.0%held
PRTOEUR PROTEON THERAPEUTICS INC–0.2%$3.3m1.34m0.0%held
GTHXEUR G1 THERAPEUTICS INC–0.1%$1.7m40,0000.0%held

Exited since Q1 2018

8 rows
AVEXIS INC no ticker9.7%$127m
CATALYST BIOSCIENCES INC no ticker1.0%$13.3m
BIOHAVEN PHARMACTL HLDG CO L no ticker0.7%$9.4m
VKTX VIKING THERAPEUTICS INC0.7%$8.9m
SNSSEUR SUNESIS PHARMACEUTICALS INC0.5%$6.7m
KRYS KRYSTAL BIOTECH INC0.4%$5.0m
EDGE THERAPEUTICS INC no ticker0.03%$337k
CTIC1USD CTI BIOPHARMA CORP0.02%$222k

Sector mix

  • Healthcare58.3%
  • Unclassified41.7%

Book over time

Every quarter on file (73)
QuarterPositionsEquity book
Q2 202684$11.5bn
Q1 202685$9.4bn
Q4 202571$9.8bn
Q3 202567$8.1bn
Q2 202563$5.9bn
Q1 202585$6.0bn
Q4 202489$7.5bn
Q3 202481$8.7bn
Q2 202478$7.6bn
Q1 202476$7.9bn
Q4 202362$6.4bn
Q3 202366$5.1bn
Q2 202354$5.3bn
Q1 202359$4.4bn
Q4 202270$4.9bn
Q3 202281$4.7bn
Q2 202288$3.8bn
Q1 202296$4.6bn
Q4 202197$5.7bn
Q3 202195$7.2bn
Q2 202192$6.2bn
Q1 202182$6.6bn
Q4 202082$7.2bn
Q3 202070$5.5bn
Q2 202057$5.1bn
Q1 202048$3.2bn
Q4 201934$3.3bn
Q3 201932$1.7bn
Q2 201925$1.9bn
Q1 201929$2.3bn
Q4 201825$1.7bn
Q3 201826$1.9bn
Q2 201827$1.5bn
Q1 201831$1.3bn
Q4 201727$1.2bn
Q3 201727$1.1bn
Q2 201722$871m
Q1 201724$815m
Q4 201627$706m
Q3 201630$969m
Q2 201632$722m
Q1 201642$782m
Q4 201537$1.0bn
Q3 201547$696m
Q2 201558$928m
Q1 201556$913m
Q4 201448$777m
Q3 201443$622m
Q2 201424$756m
Q1 201429$973m
Q4 201324$648m
Q3 201331$724m
Q2 201325$616m
Q1 201317$407m
Q4 201219$225m
Q3 201221$198m
Q2 201226$223m
Q1 201223$185m
Q4 201118$124m
Q3 201120$90.3m
Q2 201120$108m
Q1 201121$130m
Q4 201016$101m
Q3 201018$101m
Q1 201021$102m
Q4 200914$75.1m
Q2 200916$107m
Q1 200912$184m
Q4 20088$224m
Q3 200820$329m
Q2 200822$220m
Q1 200817$135m
Q4 200723$159m

Where RA Capital Management, L.P. was early

110 rows
VRTX VERTEX PHARMACEUTICALS INCQ1 20082 of 16012.5%12.5%7Exited by Q4 2014+370%
AMAG AMAG PHARMACEUTICALS INCQ2 20081 of 693.4%9.2%7Exited by Q3 2010+2.4%
GILD GILEAD SCIENCES INCQ4 20087 of 1810.7%15.8%6Exited by Q2 2020+192%
BSTC BIOSPECIFICS TECHNOLOGIES COQ1 20091 of 299.0%32.9%7Exited by Q3 2011–
ALXN ALEXION PHARMACEUTICALS INCQ2 20092 of 1476.6%9.6%5Exited by Q2 2011–
UTHR UNITED THERAPEUTICS CORP DELQ2 20092 of 1617.0%7.0%5Exited by Q2 2011+61%
ENZB ENZO BIOCHEM INCQ1 20101 of 400.6%3.9%7Exited by Q1 2014–
ACAD ACADIA PHARMACEUTICALS INCQ1 20111 of 1456.5%21.1%17Exited by Q3 2015+2485%
NVAX NOVAVAX INCQ4 20111 of 1171.0%14.4%24Exited by Q2 2022+192%
SGMOQ SANGAMO THERAPEUTICS INCQ4 20111 of 852.0%13.6%22Exited by Q4 2017+428%
BCRX BIOCRYST PHARMACEUTICALS INCQ1 20121 of 1218.0%11.1%28Held at last filing, Q2 2026+107%
VSTM VERASTEM INCQ1 20121 of 1003.6%3.6%6Exited by Q4 2020−89%
IMMU IMMUNOMEDICS INCQ1 201311 of 1110.6%4.8%6Exited by Q1 2019+492%
ENTA ENANTA PHARMACEUTICALS INCQ2 20131 of 921.3%8.8%8Exited by Q1 2025−68%
INSM INSMED INCQ2 20131 of 1804.7%6.4%9Exited by Q2 2025+538%
OMER OMEROS CORPQ2 20131 of 662.4%2.4%4Exited by Q3 2015+257%
PRTA PROTHENA CORP PLCQ2 20131 of 1011.0%6.7%4Exited by Q2 2014+197%
TXMD THERAPEUTICSMD INCQ2 20131 of 655.5%9.4%13Exited by Q3 2021−61%
PTCT PTC THERAPEUTICS INCQ3 20131 of 1270.9%2.6%7Exited by Q3 2015+124%
TGTX TG THERAPEUTICS INCQ3 20131 of 1140.4%6.8%30Exited by Q1 2022+277%
T8S TESARO INCQ4 20131 of 833.1%3.1%4Exited by Q3 2015+108%
XNCR XENCOR INCQ4 20131 of 1023.8%3.8%13Held at last filing, Q2 2026+76%
MGNX MACROGENICS INCQ4 201310 of 1040.8%2.6%16Held at last filing, Q2 2026−83%
SCYX SCYNEXIS INCQ2 20141 of 470.9%1.1%4Exited by Q2 2015+3.5%
AKBA AKEBIA THERAPEUTICS INCQ2 20142 of 1032.2%2.2%5Exited by Q3 2017−48%
TENX TENAX THERAPEUTICS INCQ3 20143 of 561.5%1.5%10Exited by Q1 2017−50%
CHRS COHERUS BIOSCIENCES INCQ4 20141 of 1053.3%5.2%6Exited by Q2 2016+30%
AUPH AURINIA PHARMACEUTICALS INCQ4 20142 of 1001.2%1.2%3Exited by Q3 2015−17%
ASND ASCENDIS PHARMA A/SQ1 20151 of 1371.9%29.9%46Held at last filing, Q2 2026+1437%
DVAX DYNAVAX TECHNOLOGIES CORPQ1 20151 of 1166.4%6.4%4Exited by Q1 2020−75%
2655787D BLUEPRINT MEDICINES CORPQ2 20151 of 1472.5%2.7%4Exited by Q2 2016−32%
COLL COLLEGIUM PHARMACEUTICAL INCQ2 20151 of 963.0%4.9%4Exited by Q2 2016+1.7%
MCRB SERES THERAPEUTICS INCQ2 20151 of 751.1%2.5%5Exited by Q3 2021−43%
ARDX ARDELYX INCQ2 20152 of 1143.0%4.4%15Exited by Q3 2021−53%
AIMT AIMMUNE THERAPEUTICS INCQ3 20151 of 742.9%2.9%6Exited by Q1 2017−19%
NTRA NATERA INCQ3 20151 of 1671.2%1.3%6Exited by Q3 2022+227%
ACRS ACLARIS THERAPEUTICS INCQ4 20151 of 1146.8%6.8%15Held at last filing, Q2 2026−80%
WVE WAVE LIFE SCIENCES LTDQ4 20151 of 12311.2%26.3%43Held at last filing, Q2 2026−64%
ONC BEIGENE LTDQ1 20164 of 1040.6%1.1%5Exited by Q2 2017+25%
NKTR NEKTAR THERAPEUTICSQ1 20165 of 1455.6%6.5%4Exited by Q4 2023−96%
PTGX PROTAGONIST THERAPEUTICS INCQ3 20162 of 1361.6%2.1%3Exited by Q2 2017−39%
4XC1 KALVISTA PHARMACEUTICALS INCQ4 20161 of 910.6%1.8%15Exited by Q2 2022+108%
KDMN KADMON HLDGS INCQ3 20173 of 762.0%2.0%2Exited by Q1 2018+8.1%
SCPH SCPHARMACEUTICALS INCQ4 20171 of 642.9%2.9%19Exited by Q1 2023−41%
SPRO SPERO THERAPEUTICS INCQ4 20171 of 441.2%1.2%3Exited by Q3 2018+25%
IFRX INFLARX NVQ4 20172 of 575.0%5.0%8Exited by Q4 2025−94%
SG7 SAGE THERAPEUTICS INCQ4 201714 of 1326.3%6.3%5Exited by Q2 2019−3.4%
SLDB SOLID BIOSCIENCES INCQ1 20181 of 951.5%6.8%34Held at last filing, Q2 2026−91%
IOVA IOVANCE BIOTHERAPEUTICS INCQ1 20186 of 1300.9%1.4%5Exited by Q2 2019−44%
RYTM RHYTHM PHARMACEUTICALS INCQ2 20183 of 1143.1%7.3%33Held at last filing, Q2 2026+255%

Concentration and tenure

18.2%
Median largest position, all quarters
The largest single position as a share of the reported equity book.
70.5%
Median top 10 weight, all quarters
The ten largest positions together, as a share of the reported equity book.
Concentrated
Style, by median largest position
3
Median completed holding, quarters